Transsexual patients are treated with high levels of synthetic sex hormones for gender reassignment and are unaware of possible eye complications. A case is reported of bilateral central retinal vein occlusions in a genotypically male individual which may be secondary to the use of synthetic sex hormones.
Case report
We present a case of a 45-year-old transsexual patient on hormone therapy who presented to the Eye Department with a left non-ischaemic central retinal vein occlusion (CRVO) reducing her vision to 6/24 (Fig. la) .
She had been commenced on 25 I-lg of ethinyloestradiol 11 years previously and was converted to Ovran (250 I-lg of levonorgestrol and 50 I-lg of ethinyloestradiol) for the last 9 years. She also had been treated with 50 I-lg of cyproterone acetate on a daily basis for 11 years. She smoked in excess of 10 cigarettes a day. Her blood pressure was 130/80 mmHg on presentation.
She was advised to stop smoking and the hormone therapy on the day of her opthalmic examination, which she duly did. No antiplatelet drugs were prescribed.
Six months later she developed a right non-ischaemic CRVO ( plasma viscosity, prothrombotic screen and protein electrophoresis were normal. Free protein S was 56% (normal values 23-63%), protein C activity 87% (normal values 70-130%), anti-thrombin 92% (normal values 75-125%) and activated protein C resistance 3.6 (normal values 2.6-3.8). No factor V Leiden test was performed as the screening test (activated protein C resistance) was negative. Her alcohol intake of 30 units per week resulted in a mild thrombocytopenia (121 X 10 9 /1) and a raised gamma-glutamyl transpeptidase (419). Her vision at present is counting fingers in the right eye and 6/18 in the left eye.
Comment
Activated protein C resistance has been described as the most common known cause of CRVO in young patients under 50 years of age.1 This view has been challenged recently? The combined oral contraceptive pill (COCP) has been implicated as major risk factor for the development of CRVO? The combination of smoking and COCP may have contributed to this patient's bilateral CRVOs. Antibodies to synthetic sex hormones4•5 such as cyproterone and ethinyloestradiol have been noted in patients with deep vein thromboses. These antibodies may act as prothrombotic factors. This is the first report of a young transsexual with bilateral CRVOs. It raises issues with respect to the long-term treatment modalities used in gender reassignment. The vasoproliferative tumour of the ocular fundus is an uncommon, benign vascular mass that can lead to exudation, retinal detachment and ultimate visual loss. It can occur as an isolated finding or be associated with a number of ocular conditions including intermediate uveitis, retinitis pigmentosa, toxoplasmic chorioretinitis, ocular toxocariasis and trauma.1-3 We present a case of such a tumour occurring in a patient with W aardenburg' s syndrome.
Case report
A 47-year-old woman with known Waardenburg's syndrome was found on routine ocular examination to have an intraocular mass in her left eye. Her visual acuity was 6/6 in both eyes. She showed several of the classic features of Waardenburg's syndrome, including white forelock, mild telecanthus and unilateral congenital deafness. Her father and son were similarly affected. Ocular features included iris heterochromia, the left iris being a uniform blue colour ( Fig. 1 ) and the right iris brown in colour apart from the superior third which was blue (Fig. 2) . Both fundi showed diffuse retinal pigment epithelial (RPE) loss with areas of pigment clumping (Fig. 3) .
The pertinent finding was in the inferior quadrant of the left eye where a 9 X 7 X 2.5 mm ill-defined pink retinal mass with surrounding subretinal exudation and overlying serous retinal detachment was found (Fig. 4 ). There were attenuated feeder vessels, but no dilated, tortuous feeder vessels as seen with the retinal capillary haemangioma associated with Von Hippel's disease. As the patient was asymptomatic, cautious observation was advised.
Comment
Vasoproliferative tumours of the ocular fundus were reported by J. Shields et al. in 1983 in a report of 12 cases.1 A subsequent series by C. Shields et al. reported 103 cases of similar lesions and categorised them into primary and 
